LifeMD soars as Cantor Fitzgerald reportedly reiterates Overweight rating following solid Q4 print
Source: SeekingAlpha
2026-03-10 11:47:51 ET
More on LifeMD
- LifeMD: Still My Favorite Bargain On The Market
- LifeMD outlines $250M+ annualized revenue run rate target by Q4 2026 amid record GLP-1 demand and expanded partnerships
- LifeMD rises on Q4 2025 beats, 2026 revenue guidance midpoint above consensus
Read the full article on Seeking Alpha
For further details see:
LifeMD soars as Cantor Fitzgerald reportedly reiterates Overweight rating following solid Q4 print
LifeMD Inc.
NASDAQ: LFMD
LFMD Trading
22.39% G/L:
$3.6901 Last:
3,978,719 Volume:
$3.50 Open:
LFMD Latest News
LFMD Stock Data
$146,092,411
39,278,882
2.54%
33
N/A
Healthcare Providers & Services
Healthcare
US
New York
